New England Research & Management Inc. Acquires 7,650 Shares of Bristol-Myers Squibb Co (BMY)

New England Research & Management Inc. grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 48.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,417 shares of the biopharmaceutical company’s stock after buying an additional 7,650 shares during the quarter. Bristol-Myers Squibb accounts for approximately 1.0% of New England Research & Management Inc.’s holdings, making the stock its 28th biggest holding. New England Research & Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,217,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Carroll Financial Associates Inc. grew its holdings in Bristol-Myers Squibb by 1.5% during the 4th quarter. Carroll Financial Associates Inc. now owns 17,024 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 248 shares during the last quarter. First Hawaiian Bank grew its holdings in Bristol-Myers Squibb by 16.6% during the 4th quarter. First Hawaiian Bank now owns 34,919 shares of the biopharmaceutical company’s stock valued at $1,816,000 after purchasing an additional 4,984 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in Bristol-Myers Squibb by 1.6% during the 4th quarter. State of Alaska Department of Revenue now owns 242,890 shares of the biopharmaceutical company’s stock valued at $12,622,000 after purchasing an additional 3,885 shares during the last quarter. Retirement Systems of Alabama grew its holdings in Bristol-Myers Squibb by 97.8% during the 4th quarter. Retirement Systems of Alabama now owns 1,488,554 shares of the biopharmaceutical company’s stock valued at $77,375,000 after purchasing an additional 736,000 shares during the last quarter. Finally, United Capital Management of KS Inc. grew its holdings in Bristol-Myers Squibb by 19.2% during the 4th quarter. United Capital Management of KS Inc. now owns 10,099 shares of the biopharmaceutical company’s stock valued at $525,000 after purchasing an additional 1,624 shares during the last quarter. Hedge funds and other institutional investors own 72.68% of the company’s stock.

Shares of NYSE BMY traded up $0.08 during midday trading on Friday, reaching $47.80. 335,014 shares of the company’s stock traded hands, compared to its average volume of 15,401,846. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $70.05. The company has a market cap of $77.01 billion, a PE ratio of 15.84, a P/E/G ratio of 1.29 and a beta of 0.98.



Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, analysts forecast that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Investors of record on Friday, January 4th will be given a dividend of $0.41 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.43%. Bristol-Myers Squibb’s dividend payout ratio is presently 54.49%.

BMY has been the topic of several analyst reports. BMO Capital Markets reiterated a “buy” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Thursday, January 3rd. Morgan Stanley dropped their target price on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, November 6th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research note on Friday, October 5th. Guggenheim began coverage on shares of Bristol-Myers Squibb in a research note on Monday, October 8th. They issued a “neutral” rating on the stock. Finally, ValuEngine downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $61.56.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/01/11/new-england-research-management-inc-acquires-7650-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Intrinsic Value

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply